Title |
Radiotherapy Dosing for Locally Advanced Non-Small Cell Lung Carcinoma: “MTD” or “ALARA”?
|
---|---|
Published in |
Frontiers in oncology, September 2017
|
DOI | 10.3389/fonc.2017.00205 |
Pubmed ID | |
Authors |
Nitin Ohri |
Abstract |
Locally advanced non-small cell lung cancer (LA-NSCLC) is typically treated with thoracic radiotherapy, often in combination with cytotoxic chemotherapy. Despite tremendous advances in the evaluation, treatment techniques, and supportive care measures provided to LA-NSCLC patients, local disease progression and distant metastases frequently develop following definitive therapy. A recent landmark randomized trial demonstrated that radiotherapy dose escalation may reduce survival rates, highlighting our poor understanding of the effects of thoracic radiotherapy for LA-NSCLC. Here, we present rationale for further studies of radiotherapy dose escalation as well as arguments for exploring relatively low radiotherapy doses for LA-NSCLC. |
X Demographics
As of 1 July 2024, you may notice a temporary increase in the numbers of X profiles with Unknown location. Click here to learn more.
Geographical breakdown
Country | Count | As % |
---|---|---|
Unknown | 1 | 100% |
Demographic breakdown
Type | Count | As % |
---|---|---|
Members of the public | 1 | 100% |
Mendeley readers
Geographical breakdown
Country | Count | As % |
---|---|---|
Unknown | 25 | 100% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Student > Bachelor | 6 | 24% |
Student > Ph. D. Student | 5 | 20% |
Student > Doctoral Student | 2 | 8% |
Researcher | 2 | 8% |
Student > Postgraduate | 2 | 8% |
Other | 4 | 16% |
Unknown | 4 | 16% |
Readers by discipline | Count | As % |
---|---|---|
Medicine and Dentistry | 13 | 52% |
Biochemistry, Genetics and Molecular Biology | 2 | 8% |
Nursing and Health Professions | 2 | 8% |
Agricultural and Biological Sciences | 1 | 4% |
Physics and Astronomy | 1 | 4% |
Other | 1 | 4% |
Unknown | 5 | 20% |